All News
DSB Reports and Updates - September 2016
Updates and journal articles on opioids, drug induced sarcoidosis, cancer and cancer recurrence risks with TNF inhibitors and biologics, and FDA labeling changes.
Read Article
Adalimumab Lowers Risk of Uveitis Flares in Visual I Study
Rheumatologists may encounter patients with intermediate, posterior and pan-uveitis as part of certain rheumatic diseases such as Behcet’s, but more frequently may be called on to co-manage these patients with steroid sparing agents.
Read Article
The RheumNow Week in Review – 9 September 2016
Dr. Jack Cush reviews highlights from the past week on RheumNow.com, including IBD/TNFi and cancer risk, fracture nonunion, PMR worse in women, not treating asymptomatic hyperuricemia, and shingles followed by stroke.
Read Article
Shingles Plus Autoimmune Disease Hikes Stroke Risk
Patients with autoimmune inflammatory diseases who develop herpes zoster are at increased risk of stroke for the subsequent 3 months, with risks diminishing thereafter, analysis of Medicare data showed.
Read Article
RheumNow Week in Review – 2 September 2016
Dr. Jack Cush reviews highlights from this week in RheumNow:
Read Article
Flares Portend Damage in Rheumatoid Arthritis - Time for a New Strategy?
Disease flares are common in rheumatoid arthritis (RA), often causing patients to seek additional care, if not medication.
The frequency of flares varies amongst studies in different populations. But the consequence of flares has only recently been studied.
Read Article
Another Biosimilar Approval - Etanercep-szzs by Novartis
Yesterday the U.S. Food and Drug Administration approved a new biosimilar, Erelzi, (etanercept-szzs), for the same multipile indications as the originator Enbrel, including rheumatoid arthritis, plaque psoriasis, Erelzi, will be generically labelled as etanercept-szzs.
Read Article
RheumNow Week in Review – 26 August 2016
Dr. Jack Cush reviews news and journal reports from the past week on RheumNow.com.
Read Article
Prior Cancer Patients May Safely Receive TNF Inhibitors or Rituximab
Current guidelines regarding the use of biologics in patients who have previously had a malignancy are based more on opinion than evidence.
Read Article
Adalimumab Controls Non-Infectious Uveitis in VISUAL II Study
It has long been observed that patients receiving monoclonal antibody based anti-TNF (TNFi) therapies for spondylitis or psoriatic disease have less inflammatory eye complications, such as uveitis. These agents have become common interventions based on these observational results.
Read Article
Risk of Sepsis or Death Lower with Biologics in Rheumatoid Arthritis
Researchers from Germany have analyzed their large prospective rheumatoid arthritis (RA) registry to address whether being on biologic therapies leads to poorer outcomes - namely sepsis or death, following a serious infection (SIE).
Read Article
ARCTIC Study Shows No Benefit to Ultrasound Remission in RA
The goal in rheumatoid arthritis (RA) treatment is remission. But what level or method of remission is best?
Read Article
Remicade Patent Infringements Denied: Opens Door for New Biosimilars
A U.S. court has affirmed its decision that the patent for Johnson & Johnson's drug Remicade is invalid. This new ruling favors the intent of Celltrion and Pfizer, who are seeking to bring their biosimilar versions of infliximab to market in the near future.
Read Article
Fewer Psoriasis Patients Satisfied with Current Treatments
A new national survey in the United States of nearly 600 individuals with psoriasis, reveals that although patients have numerous treatment options, they have difficulty finding treatment plans that work. In addition, respondents reported a heavy emotional toll, with many feeling isolated and stigmatized due to the condition.
Read Article
RheumNow Week in Review – 12 August 2016
Watch Dr. Cush review 13 highlights from this week on RheumNow.
Read Article
No Added Lymphoma Risk with TNF Inhibitor Use
Warnings of cancer, especially lymphoma, have accompanied the development and promotion of tumor necrosis factor inhbitors (TNFi) in the treatment of RA and other inflammatory disorders.
Read Article
Etanercept May Lower Alzheimers Risk in Rheumatoid Arthritis
The pathogenesis of Alzheimer's disease (AD) is unknown but some have speculated a role for inflammation.
Read Article
Severe, Refractory Psoriasis in HIV-Positive Patients: Are TNF Inhibitors a Solution?
Psoriasis and psoriatic arthritis are more prevalent, often more severe, and sometimes refractory to conventional treatments in HIV-positive patients, but clinicians are understandably concerned about moving on to immunosuppressive anti-tumor necrosis factor (TNF) agents when other treatments fai
Read Article
Biosimilars are Bioequivalent to Original TNF Inhibitors
Chingcuanco and coinvestigators have reported on their comparative analysis of biosimilars and their originator TNF inhibitors in the current issue of Annals of Internal Medicine. (Citation source: http://buff.ly/2arTd1q)
Read Article
RheumNow Week in Review - 29 July 2016
Dr Jack Cush reviews this week's highlights from RheumNow.com.
Read Article